Ceftibuten (hydrate)

Ceftibuten is an orally bioavailable broad-spectrum cephalosporin antibiotic that inhibits the growth of B. catarrhalis, H. influenzae, pathogenic Neisseria, Streptococcus, penicillin-susceptible S. pneumoniae, and eleven Enterobacteriaceae strains (MICs = 0.25, =0.06, =0.06, 0.5-1, 4, and =0.06-0.5 µg/ml, respectively). Ceftibuten is also active against E. coli expressing beta-lactamase type I, III, and V and K. oxytoca expressing beta-lactamase type IV (MICs = 8, 0.25, 0.5, and =0.06 µg/ml, respectively) as well as a panel of eight bacterial stains expressing plasmid-encoded extended spectrum beta-lactamases, including E. coli CTX-M and K. pneumoniae SHV-2 (MICs = 1 and 0.25 µg/ml, respectively). In vivo, ceftibuten reduces the number of mice killed within 6 days of a K. pneumoniae, E. coli, S. pneumoniae, or S. aureus infection by 50% when administered subcutaneously at doses of 0.125, 2, 1,024, and >512 mg/kg, respectively. Formulations containing ceftibuten have been used in the treatment of bacterial infections including bronchitis, pneumonia, and enteritis.Formal Name: (6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-4-carboxy-1-oxo-2-buten-1-yl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, dihydrate. CAS Number: 118081-34-8. Synonyms: SCH 39720. Molecular Formula: C15H14N4O6S2 . 2H2O. Formula Weight: 446.5. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 2 mg/ml, DMSO: 5 mg/ml, PBS (pH 7.2): 0.1 mg/ml. lambdamax: 218, 262 nm. SMILES: OC(C1=CCS[C@@]([C@@H]2NC(/C(C3=CSC(N)=N3)=C\CC(O)=O)=O)([H])N1C2=O)=O. InChi Code: InChI=1S/C15H14N4O6S2/c16-15-17-7(5-27-15)6(1-2-9(20)21)11(22)18-10-12(23)19-8(14(24)25)3-4-26-13(10)19/h1,3,5,10,13H,2,4H2,(H2,16,17)(H,18,22)(H,20,21)(H,24,25)/b6-1-/t10-,13-/m1/s1. InChi Key: UNJFKXSSGBWRBZ-BJCIPQKHSA-N.